Immobilized TL1A/TNFSF15 Protein,Human(UA040184) can bind Tulisokibart. The EC50 for this effect is 5.461 ng/mL.
Product Details
Product Details
Product Specification
| Clone Number | S-SC042 |
| Antibody Type | Recombinant mAb |
| Application | Blocking of TL1A signaling Functional assays |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
Tulisokibart is a humanized monoclonal antibody targeting Tumor Necrosis Factor-Like Cytokine 1A (TL1A), currently in clinical development, primarily for the treatment of moderate to severe active ulcerative colitis. It works by binding with high affinity and specificity to the TL1A protein, inhibiting its interaction with the DR3 receptor, thereby suppressing pro-inflammatory and pro-fibrotic pathways to achieve therapeutic effects in inflammatory bowel disease.
Picture
Picture
SEC-HPLC

ELISA

